JPRN-jRCT2021230017招募中3 期
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis - CROSSING
Ageishi Yuji0 个研究点目标入组 360 人开始时间: 2023年7月25日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 360
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 12age old 至 <= 80age old（—）
- 性别
- All
入选标准
- •1. Participant must be 12 to 80 years of age inclusive, at the time of signing the informed consent/assent.
- •2. Weight 40 kg or more at Visit 1.
- •3.Established diagnosis of EoE with a previous EGD and esophageal biopsy confirming a diagnosis of EoE.
- •4. Participants who have symptomatic EoE as defined by a history of on average at least 2 episodes of dysphagia (any severity of food going down slowly or being stuck in the throat) per week in the 4 weeks prior to Visit 1.
- •5. Must remain on a stabilized diet for at least 8 weeks prior to Visit 1 and during the course of the study (stable diet is defined as no initiation of single or multiple elimination diets or reintroduction of previously eliminated food groups).
- •6. May be on any background PPI and/or STC, during the course of the study, as long as background medications have been stable for at least 8 weeks prior to the screening/run-in period (Visit 1) and there is agreement not to change background medication or dosage unless medically indicated, during the screening/run-in and treatment period.
- •7. Participants currently on leukotriene inhibitors and/or steroid treatments for asthma or allergies that are inhaled or administered intranasally, must report a stable dose for at least 4 weeks prior to the screening/run-in period (Visit 1).
- •8. If a medication for EoE (for example PPI and/or STC) is discontinued prior to the screening/run-in, there should be a washout period of at least 8 weeks prior to Visit 1. Discontinuation of any marketed biologic (monoclonal or polyclonal antibody) should have a washout period of 4 months or 5 half-lives prior to Visit 1, whichever is longer.
- •9. Participants should have previously documented standard of care treatment, which could include PPI and/or STC and/or diet.
排除标准
- •1. Other gastrointestinal disorders such as active Helicobacter pylori infection, history of achalasia, esophageal varices, Crohn's disease, ulcerative colitis, inflammatory bowel disease, celiac disease, eosinophilic enteritis, colitis, diverticulitis, irritable bowel syndrome, or other clinically significant gastrointestinal conditions as per Investigator discretion.
- •2. Esophageal stricture that prevents the easy passage of a standard endoscope or any critical esophageal stricture that requires dilation at screening.
- •3. Use of a feeding tube, or having a pattern of not eating solid food >3 days of week. Solid food is defined as food that requires chewing before swallowing.
- •4. Hypereosinophilic syndrome.
- •5. EGPA vasculitis.
- •6. Esophageal dilation performed within 8 weeks prior to screening.
研究者
相似试验
已完成
不适用
Comparative Efficacy and Safety of Tezepelumab and Dupilumab in Patients with Inadequately Controlled Asthma According to Thresholds of Type 2 Inflammatory Biomarkers: A Systematic Review and Network Meta-AnalysisBronchial asthmaJPRN-UMIN000044672Showa University School of Medicine5,524
尚未招募
3 期
The use of tocilizumab in patients with severe COVID 19 pneumonia - a trial to know its efficacy in those on steroidsCTRI/2020/12/029793aveen Naik B
进行中（未招募）
不适用
Safety and Efficacy of Adalimumab in Patients with Psoriatic Arthritis (PsA)- An Open-Label, Multinational Study to Evaluate the Response to Every-Other Week Adalimumab When Added to Insufficient Standard Therapy Including Patients who Failed Prior Treatment With Other TNF-Inhibitors (STEREO) - STEREOPsoriatic ArthritisEUCTR2005-001185-14-BEAbbott GmbH & Co. KG500
进行中（未招募）
不适用
Safety and Efficacy of Adalimumab in Patients with Psoriatic Arthritis (PsA)- An Open-Label, Multinational Study to Evaluate the Response to Every-Other Week Adalimumab When Added to Insufficient Standard Therapy Including Patients who Failed Prior Treatment With Other TNF-Inhibitors (STEREO) - STEREOPsoriatic ArthritisEUCTR2005-001185-14-SEAbbott GmbH & Co. KG500
进行中（未招募）
不适用
Safety and Efficacy of Adalimumab in Patients with Psoriatic Arthritis (PsA)- An Open-Label, Multinational Study to Evaluate the Response to Every-Other Week Adalimumab When Added to Insufficient Standard Therapy Including Patients who Failed Prior Treatment With Other TNF-Inhibitors (STEREO) - STEREOPsoriatic ArthritisEUCTR2005-001185-14-DEAbbott GmbH & Co. KG500